Mutation specific biosensors to accelerate kinase drug development

KinCon biolabs is a biotech startup based in Innsbruck Austria. We develop a constantly expanding platform of unique kinase activity biosensors.

Our Mission

Precision medicine

Reviving enzymes

KinCon biolabs advances the identification of the most efficient, mutation-specific kinase drug candidates to accelerate drug development.

We are setting out to reactivate compartmentalized and mutated enzyme pathways to identify first in class treatments for neurodegenerative disorders.

Profiling Kinase Conformations

Technology

patient mutations

drug selectivity

drug efficacy

> 500 kinases

Kinases are central molecular switches. Mutations in kinase encoding genes contribute to the etiology and progression of cancer and other diseases. There is a constant need for novel effective kinase-specific drugs.

The KinCon biosensor platform allows the tracking of drug-induced changes of the kinase conformation under physiological relevant conditions.

Kinase activity measurements in living cells
Full-length kinase biosensors are expressed in the target cell-line of choice.
Simple integration of patient mutations for precision medicine
Any mutation of interest can be integrated into the respective biosensor to determine mutation specific drug (candidate) efficacies and specificities.
Systematic analysis
Our technology allows dose- and time-dependent drug profiling in a high content format.

Behind the scenes

Meet the KinCon biolabs Team

Team
Scientific advisory board

Eduard Stefan

CEO | Co-Founder

Edi is the inventor of the KinCon technology, holds a PhD in genetics and brings more than 15 years of experience in studying the functions of various kinases. He is a group-leader in the department of biochemistry at the University of Innsbruck.

Philipp Tschaikner

CSO | Co-Founder

Philipp holds a PhD in molecular cell-biology. He is responsible for steering the development of the biosensor platform and implementing our customer-projects.

Alexandra Fritz

Lab Assistant

Alex holds a master’s degree in biotechnology and is responsible for most of the benchwork at KinCon biolabs.

No items found.

Are you interested in our biosensors or just want to connect with us?

Just fill out the form below.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

News & Publications

See all

October 2022

Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures

April 2021

mTORC2 controls the activity of PKC and Akt by phosphorylating a conserved TOR interaction motif

March 2020

Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico

KinCon biolabs GmbH is a University of Innsbruck spin-off company supported by funding from the Austrian Research Promotion Agency (FFG) Spin-off Fellowship and Austria Wirtschaftsservice (AWS) Preseed program.

Swipe for more

Mutation specific biosensors to accelerate kinase drug development

KinCon biolabs is a biotech startup based in Innsbruck Austria. We develop a constantly expanding platform of unique kinase activity biosensors.

Our Mission

Technology

Technology

Kinase activity measurements in living cells

Simple integration of patient mutations for precision medicine

Systematic analysis

Behind the scenes

Are you interested in our biosensors or just want to connect with us?

Just fill out the form below.

News & Publications

Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures

mTORC2 controls the activity of PKC and Akt by phosphorylating a conserved TOR interaction motif

Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico

Adress